A carregar...
State of the art in anti-cancer mAbs
Following Milstein’s discovery, the monoclonal antibodies (mAbs) became a basic tool for biomedical science. In cancer field, since the first mAb was approved by the FDA a great improvement took place making of them a therapeutic option for many cancer types in the current clinical practice. Today,...
Na minha lista:
| Publicado no: | J Biomed Sci |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5319201/ https://ncbi.nlm.nih.gov/pubmed/28219375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12929-016-0311-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|